

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hiroyuki FUJITA

Serial No.: 09/663,709

Filed: September 18, 2000

For: ANGIOTENSIN CONVERTING ENZYME INHIBITOR

Group Art Unit: 1632

Examiner: Not yet assigned



p#6

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

RECEIVED
DEC 21 2000
TECH CENTER 1600/2900

Honorable Commissioner of Patents
Washington, D.C. 20231

December 19, 2000

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, WESTERMAN, HATTORI,
MCLELAND & NAUGHTON



Nicolas E. Seckel
Attorney for Applicant
Reg. No. 44,373

Atty. Docket No. 001200
1725 K Street, N.W., Suite 1000
Washington, DC 20006
Tel: (202) 659-2930
Fax: (202) 887-0357
NEs/kah

Enclosures: PTO-1449 and 2 references